AMA recently published a detailed study of over 180+ pages in its repository on ‘Retinal Drugs’ market  covering interesting aspects of market with supporting development scenario till 2025. The study provides market size break-up by revenue and volume* for  emerging countries and important business segments along with commentary on trending factors, growth drivers. Profiled players in study from the coverage used under bottom-up approach are
Bayer AG (Germany)

F. Hoffmann-La Roche (Switzerland)

Bausch & Lomb (United States)

Novartis International AG (Switzerland)

Regeneron Pharmaceuticals, Inc. (United States)

Johnson and Johnson Vision (United States)

Merck & Co. (United States)

Shire Plc (Untied States)

Janssen Biotech, Inc. (United States)

Teva Pharmaceutical Industries Ltd. (Israel)

Retinal is related to the retina of the eye which is a thin layer of tissue. Major causes of retinal diseases are retinal detachment, diabetic retinopathy, epiretinal membrane, macular hole, macular degeneration, and others. Some of the major symptoms of retinal diseases are seeing floating specks, blurred, defects in the side vision and lost vision. In the last few years, there is a significant increase in retinal diseases across the world. For instance, in 2016, according to an article published by American Academy of Ophthalmology, more than 93 million people had diabetic retinopathy across the worldwide, out of which more than 4.2 million patients were from the United States. Therefore, the rising number of patients across worldwide and increasing consumer buying behavior regarding retinal drugs products are some of the major factors which affect the growth of the market in the future.

Next step one should take to boost sales? Track latest strategic steps and current scenario analysis of the market @

Market Segmentation
by  Type (Wet AMD, Diabetic Retinopathy, DME, RVO, Mcnv), Prescription Type (Prescription Ophthalmic Drugs, OTC), Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, Others)

Make an enquiry before buying this Report @

What’s Trending in Market:
One of the latest trends of this Market is Increasing Usage of Combination Therapies

Growth Drivers:

Rising Old Population and Corresponding Increase in Technology Advancement of Retinal Drugs across the World

Increasing Number of Patients Regarding the Incidence of Eye-Related Diseases


Issue related to Risk of Side Effects associated with Retinal Drugs

View Detailed Table of Content @

Country level Break-up includes:
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)
Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Strategic Points Covered in Table of Content of Global Retinal Drugs Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Retinal Drugs market

Chapter 2: Exclusive Summary – the basic information of the Retinal Drugs Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Retinal Drugs

Chapter 4: Presenting the Retinal Drugs Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.


Chapter 5: Displaying the by Type, End User and Region 2013-2018

Chapter 6: Evaluating the leading manufacturers of the Retinal Drugs market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source


* Customized Section/Chapter wise Reports or Regional or Country wise Chapters are also available.

Buy this report @

Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
[email protected]

Ph: +1 (206) 317 1218